Lilly(Eli) & Company
NYSE: LLY
$887.16
+$1.61 (+0.2%)
Closing Price on October 4, 2024
LLY Articles
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of July and added some color.
Published:
A new research report from Merrill Lynch features the catalyst-driven stocks ideas for the third quarter. These four had the largest upside to the posted target prices.
Published:
How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?
Published:
When the American Society of Clinical Oncology (ASCO) decided to create a rating scale for cancer drugs, it certainly must have expected to get some pushback.
Published:
Last Updated:
Thursday's top analyst upgrades, downgrades and initiations include Amazon, CenturyLink, Fitbit, Mobileye, Eli Lilly, Netflix and AT&T.
Published:
ThinkstockAs we get closer to second quarter earnings, many investors on Wall Street and Main Street are starting to concentrate on having stocks in portfolios that can not only hit or beat the...
Published:
Eli Lilly has made a big splash in the market over the past year. A key analyst sees this trend continuing despite some potential near-term headwinds.
Published:
Thursday's top analyst upgrades, downgrades and initiations include Bankrate, Eli Lilly, Embraer, Oracle and Southwest Airlines.
Published:
Wednesday's top analyst upgrades, downgrades and initiations include Arista Networks, Baidu, Chevron, Lexmark International, Occidental Petroleum and Salesforce.com.
Published:
24/7 Wall St. has put together a list of companies that have outperformed the market this past week.
Published:
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Published:
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair...
Published:
Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.
Published:
A recent research note from SunTrust Robinson Humphrey highlights some outstanding stocks that are out of favor.
Published:
In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising first-quarter earnings.
Published: